Conclusions and Clinical Importance: Valacyclovir might not be an effective short-term antiviral treatment but efficacy in treatment of EMPF is unknown.
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| INTRODUCTION
Equine multinodular pulmonary fibrosis (EMPF) is a chronic, progressive, interstitial lung disease of adult horses. The disease is characterized histologically by marked interstitial fibrosis and mixed inflammatory cell infiltration of the lungs. 1, 2 The exact pathogenesis and predisposing factors currently remain elusive; however, there is increasing evidence that equine herpesvirus-5 (EHV-5) is associated with EMPF. Equine herpesvirus-5 has been detected from the lungs of the majority of EMPF cases described in the literature, suggesting an etiological link. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] 11 Furthermore, pulmonary fibrosis has recently been experimentally induced with EHV-5 isolated from the lungs of horses with EMPF and inoculated endoscopically into the accessory lung lobe of clinically normally horses. Nodular pulmonary fibrosis and myofibroblast induction occurred in the EHV-5 inoculated horses. 3 inciting cause of epithelial injury in EMPF cases, with the development of an unrestrained, disproportionate healing response resulting in pulmonary fibrosis. 4, 7 Current treatment of EMPF cases is focused on attempting to control the ongoing pulmonary inflammation and prevent further fibrosis. 5, 7 Corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) are frequently used to reduce pulmonary inflammation and control pyrexia. Tetracycline antimicrobial drugs, including minocycline and doxycycline, can attenuate the activity of metalloproteinases and are beneficial in murine models of pulmonary disease. 16 Tetracycline antimicrobial drugs are often employed for their antifibrotic and anticollagenase effects. 5 Use of the antiviral prodrug valacyclovir has been described in 1 horse with EMPF that was reported to be clinically healthy 2 years after treatment. 11, 17 Valacyclovir is produced by ester linking of acyclovir with the amino acid L-valine, increasing the drug's oral bioavailability. After oral administration, the prodrug valacyclovir is promptly hydrolysed to acyclovir, an inhibitor of viral DNA polymerase. Valacyclovir has been used both prophylactically and therapeutically in equine herpesvirus-1 (EHV-1) outbreaks to decrease viremia and virus shedding. 18 Treatment of horses with PO adminis- 
| Sample analysis
The study was designed as a prospective clinical trial during which horses diagnosed with EMPF would undergo 10 days of treatment with PO administered valacyclovir. This duration of valacyclovir treatment was selected based on previous evidence that 1-2 weeks of PO administered valacyclovir treatment was sufficient to decrease viremia and virus shedding of EHV-1 in horses. 18 Nucleic acid extraction from whole blood, NS and BALF were performed as previously described. 20 Briefly, an automated nucleic acid extraction system (CAS-1820 X-tractor Gene) was used. Blood, NS, and BALF were assayed for the presence of the glycoprotein B (gB) gene of EHV-5. All samples were assayed for the presence of the housekeeping gene eGAPDH as previously described to ensure sample quality and effectiveness of nucleic acid extraction. 21 Standard curves for EHV-5 and eGAPDH, expressed as EHV-5 gB gene copies per million cells, were performed to allow complete quantification of EHV-5 target molecules. 20 
| Acyclovir assay
Serum concentrations of acyclovir were determined by HPLC. Blood samples were collected from all horses during the predicted steadystate phase of treatment (day 4) to determine steady-state peak and trough plasma acyclovir concentrations. 19 Peak samples were col- analysis. Plasma acyclovir concentrations were determined by HPLC, as previously described. 19 
| Data analysis
A Mann Whitney test was used to compare the differences in EHV-5 gB genes per million cells measured by qPCR between day 0 and day 10 for each of the 3 sample types (whole blood, NS, and BALF).
P values <.05 were considered statistically significant.
| RESULTS
There was no statistical difference in median EHV-5 viral load between day 0 and day 10 as measured by qPCR in whole blood, NS, and BALF (Figure 1) . The median and range EHV-5 viral loads in gB gene copies per million cells for each sample type are included in Table 1 
| DISCUSSION
In our study, valacyclovir was not effective at decreasing the viral load of EHV-5 in horses with EMPF. There was no significant change in EHV-5 viral load in any of the 3 sample types measured.
Individual variation in EHV-5 viral load was evident in the samples tested over the 10 days of treatment but median values were consistent. In all horses tested, EHV-5 viral load in BALF increased after the treatment, indicating ongoing viral replication in the lungs. Acyclovir administered PO has poor bioavailability and therefore the use of the prodrug valacyclovir is necessary to ensure adequate acyclovir plasma concentrations. [22] [23] [24] Acyclovir has a time-dependent pharmacokinetic-pharmacodynamic pattern with trough acyclovir plasma concentrations most predictive of acyclovir efficacy. 18 Mean trough acyclovir concentration achieved was slightly lower but comparable to the mean trough concentration achieved in the previous Maxwell et al. study. 19 The mean peak acyclovir concentrations attained were considerably lower than those achieved previously. 19 These differences were likely attributable to the delivery method of the valacyclovir. In our study, the valacyclovir tablets were administered PO via a syringe in contrast to the intragastric delivery utilized in the previous study. Oral administration of valacyclovir allowed ease of delivery of the drug but might have resulted in a partial loss of the dose. 
